Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

January 5, 2023

Study Completion Date

February 1, 2023

Conditions
Osteoarthritis, Knee
Interventions
DIETARY_SUPPLEMENT

Fisetin

Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.

DRUG

Placebo oral capsule

Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.

Trial Locations (1)

81657

The Steadman Clinic, Vail

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Office of Naval Research (ONR)

FED

lead

Steadman Philippon Research Institute

OTHER

NCT04210986 - Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial | Biotech Hunter | Biotech Hunter